Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:

NCT ID: NCT02204241 Completed - Multiple Myeloma Clinical Trials

Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients

CCD
Start date: June 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This protocol is a phase I/II multicenter study designed to assess the safety and the efficacy of the proposed combinations as up-front treatment in elderly Multiple Myeloma (MM) patients.

NCT ID: NCT02203825 Completed - Multiple Myeloma Clinical Trials

Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

Start date: March 2015
Phase: Phase 1
Study type: Interventional

This Phase I clinical trial is evaluating chimeric-antigen receptor (CAR) T-cells (CM-CS1 T cells) which recognize NKG2D-ligands on the surface of cancer cells. This study evaluates the safety and feasibility of administering a single intravenous dose of CM-CS1 CAR T-cells to patients with AML, MDS-RAEB and Multiple Myeloma.

NCT ID: NCT02197221 Completed - Multiple Myeloma Clinical Trials

Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma

IFM2014-02
Start date: January 2015
Phase: Phase 3
Study type: Interventional

Phase III multicenter randomized, open-label study comparing the efficacy of a combined high dose chemotherapy using melphalan and bortezomib versus melphalan alone followed by stem cell transplant in frontline multiple myeloma patients, non-progressive after induction therapy.

NCT ID: NCT02192775 Completed - Multiple Myeloma Clinical Trials

UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus

Start date: March 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the clinical efficacy of MV-NIS (measles virus-sodium iodide symporter) therapy for people with relapsed/refractory myeloma when given with cyclophosphamide

NCT ID: NCT02189343 Completed - Multiple Myeloma Clinical Trials

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Start date: September 15, 2014
Phase: Phase 1
Study type: Interventional

To determine the maximum tolerated dose (MTD), if present, and dose schedule of ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma.

NCT ID: NCT02188537 Completed - Myeloma Clinical Trials

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

Start date: December 2, 2014
Phase: Phase 2
Study type: Interventional

Trial objectives: To decide whether the addition of nelfinavir to the approved antimyeloma therapy with bortezomib and dexamethasone has sufficient activity in proteasome inhibitor-resistant myeloma patients to merit further clinical investigation in a prospective controlled trial. Additional research questions: To collect myeloma cell samples from proteasome inhibitor-resistant myeloma patients for the assessment of the biology of proteasome inhibitor resistance and the identification of predictive markers for response to nelfinavir-based antimyeloma therapy.

NCT ID: NCT02186834 Completed - Multiple Myeloma Clinical Trials

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Start date: September 23, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to determine the recommended doses of selinexor in combination with liposomal doxorubicin and dexamethasone for patients with relapsed and refractory myeloma. In addition, the study will assess whether this combination with effective for patients with multiple myeloma.

NCT ID: NCT02185820 Completed - Multiple Myeloma Clinical Trials

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

CPD
Start date: June 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This protocol is a phase I/II multicenter study designed to assess the safety and the efficacy of the proposed combinations in relapsed and/or refractory Multiple Myeloma (MM) patients.

NCT ID: NCT02184533 Completed - Multiple Myeloma Clinical Trials

Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer

Start date: July 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum-tolerated dose (MTD) of sodium selenite when administered in combination with radiation therapy to subjects with metastatic cancer based on safety and tolerability.

NCT ID: NCT02182141 Completed - Multiple Myeloma Clinical Trials

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

Start date: April 2003
Phase: Phase 1
Study type: Interventional

Maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamics